FrancoisMLebelMD

Internal Medicine • Deerfield, IL

Physician

Join to view full profile

Dr. Lebel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lebel's full profile

Already have an account?

Office
1 Baxter Pkwy
# 5-2w
Deerfield, IL 60015
Phone+1 847-948-4135

Education & Training

University of Ottawa Faculty of MedicineClass of 1977, MD

Certifications & Licensure

MI State Medical License 1999 - 2019
American Board of Internal Medicine Internal Medicine

Clinical Trials

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Start of enrollment: 2017 Sep 26
Terminated
Phase 1, Phase 2
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 Start of enrollment: 2018 Jun 18
Completed
Phase 1
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Start of enrollment: 2018 Sep 05
Completed
Phase 1

Publications & Presentations

PubMed

6 citations
Techniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled ad...
Sandra Connolly, Helen Korzemba, George Harb, Francois Lebel, Christine Syltevik
Journal of Infusion Nursing. 2011-09-01
46 citations
Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administr...
George Harb, Francois Lebel, Jean P. Battikha, Jeffrey W Thackara
Current Medical Research and Opinion. 2010-01-15
1 citations
Cryptococcal cerebrospinal fluid shunt infection treated with fluconazole.
Daniel Eymard, François Lebel
The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses. 1993-07-01

Lectures

Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022September 10th, 2022
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021September 18th, 2021
Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021April 10th, 2021
Join now to see all